Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI)

NCT02819700 | Completed

• 1 other identifier: PI11-PR-GODEFROY-2
• Study Type: observational
• Target: 49
• Locations: 1 country
• Sites: 2

Brief Summary

Behavioural disorders are very common right from the initial stage of dementia and contribute to loss of autonomy. Behavioural dysexecutive disorders have a particular status due to their prevalence and their diagnostic importance, as they often constitute the initial symptoms of Frontotemporal Dementia (FTD), Semantic Dementia (SD) and Huntington's disease (HD) and they are classically more frequent in vascular dementia (VaD) than in Alzheimer's disease (AD). The presence of these disorders at the stage of Mild Cognitive Impairment (MCI) has only been partially evaluated and would increase the risk of progression to dementia. These classical data are based on non-standardized assessments and non-validated diagnostic criteria. The Groupe de Reflexion pour l'Evaluation des Fonctions EXécutives (GREFEX) has developed a standardized assessment tool for behavioural dysexecutive disorders, the Behavioural Dysexecutive Syndrome Inventory (BDSI) and has validated diagnostic criteria for this syndrome.

Conditions

Frontotemporal Dementia; Huntington Disease; Alzheimer Disease; Semantic Dementia; Dementia, Vascular

Keywords

behavioural disorders

Outcome Measures

Primary Outcomes (1)

• ISDC (Behavioural Dysexecutive Syndrome Inventory)

  Behavioural Dysexecutive Syndrome Inventory

  Day 0

Interventions

prevalence of behavioural dysexecutive syndrome BEHAVIORAL

Behavioural Dysexecutive Syndrome Inventory (ISDC)

Eligibility Criteria

• Age: 40 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

French-speaking subjects between the ages of 40 and 85 years with an MMSE score \> 15/30, followed for AD or MCI or VaD or FTD or SD or HD will be selected by their neurologist during a routine memory assessment visit.

You may qualify if:

• Support to the consultation memory for a neurological disease ( frontotemporal dementia , vascular dementia , Alzheimer's disease , mild cognitive disorder, Huntington's disease ( with genetic diagnosis confirmed : number of CAG triplets \> 36 symptomatic : UHDRS score ≥5 ) with MMS \> 15
• Age 40 to 85 years
• French
• Informing reliable
• Agreeing to participate in the study.

You may not qualify if:

• Presence of other disease disturbing behavior ( current depressive syndrome , schizophrenia, psychosis , past psychiatric disorders requiring a stay \> 2 days in a specialized environment ) or cognition (mental retardation , illiteracy , respiratory failure, kidney , liver , heart ) or preventing the realization of the tests ( perceptual or motor deficit ) intrecérébrale pacing therapy or stem cell transplant , patient protected ( under supervision or guardianship ) , pregnant and / or breastfeeding and lack of consent

Sponsors & Collaborators

• Centre Hospitalier Universitaire, Amiens: lead

Study Sites (2)

CHU Amiens

Amiens, 80054, France

Location

CHU Strasbourg

Strasbourg, 67091, France

Location

MeSH Terms

Conditions

Frontotemporal Dementia; Huntington Disease; Alzheimer Disease; Dementia, Vascular; Mental Disorders

Condition Hierarchy (Ancestors)

Frontotemporal Lobar Degeneration; Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; TDP-43 Proteinopathies; Neurodegenerative Diseases; Proteostasis Deficiencies; Metabolic Diseases; Nutritional and Metabolic Diseases; Neurocognitive Disorders; Basal Ganglia Diseases; Chorea; Dyskinesias; Movement Disorders; Heredodegenerative Disorders, Nervous System; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cognition Disorders; Tauopathies; Cerebrovascular Disorders; Intracranial Arteriosclerosis; Intracranial Arterial Diseases; Leukoencephalopathies; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Olivier GODEFROY, MD, PhD

  CHU Amiens

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 24, 2016
• First Posted: June 30, 2016
• Study Start: January 29, 2013
• Primary Completion: January 28, 2018
• Study Completion: January 28, 2018
• Last Updated: July 20, 2020

Record last verified: 2020-07

Locations

FR (2)